Anixa Biosciences financials
$2.85+2.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Jul 31 | Q2 '26 Apr 30 | Q1 '26 Jan 31 | Q4 '25 Oct 31 | Q3 '25 Jul 31 | Q2 '25 Apr 30 | Q1 '25 Jan 31 | Q4 '24 Oct 31 | Q3 '24 Jul 31 | Q2 '24 Apr 30 | Q1 '24 Jan 31 | Q4 '23 Oct 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$2.7M | -$2.6M | -$2.7M | -$2.9M | -$2.4M | -$3.0M | -$3.4M | -$3.2M | -$3.6M | -$3.5M | -$3.6M | -$3.1M |
| Net income | -$2.6M | -$2.5M | -$2.6M | -$2.7M | -$2.3M | -$2.8M | -$3.2M | -$2.9M | -$3.3M | -$3.1M | -$3.3M | -$2.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.08 | $-0.07 | $-0.08 | $-0.08 | $-0.07 | $-0.09 | $-0.10 | $-0.09 | $-0.10 | $-0.10 | $-0.10 | $-0.09 |
| EBITDA | -$2.7M | -$2.6M | -$2.7M | -$2.9M | -$2.4M | -$3.0M | -$3.4M | -$3.2M | -$3.6M | -$3.5M | -$3.6M | -$3.1M |
| Operating cash flow | -$1.8M | -$1.7M | -$2.6M | -$1.3M | -$1.5M | -$1.5M | -$2.9M | -$927.0K | -$2.6M | -$1.5M | -$2.3M | -$2.0M |
| Free cash flow | -$1.8M | -$1.7M | -$2.6M | -$1.3M | -$1.5M | -$1.5M | -$2.9M | -$927.0K | -$2.6M | -$1.5M | -$2.3M | -$2.0M |
| Diluted shares | 34.2M | 33.6M | 33.2M | 32.9M | 32.5M | 32.2M | 32.2M | 32.2M | 32.1M | 31.9M | 31.4M | 31.1M |
Balance sheet
| Period end | Jul 31 | Apr 30 | Jan 31 | Oct 31 | Jul 31 | Apr 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.4M | $1.5M | $1.5M | $1.2M | $1.5M | $1.9M |
| Short-term investments | $12.5M | $12.2M | $12.7M | $13.9M | $14.5M | $13.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $15.1M | $14.9M | $15.2M | $16.1M | $17.7M | $17.0M |
| Total liabilities | $1.9M | $1.6M | $1.4M | $2.1M | $2.2M | $2.1M |
| Shareholders' equity | $13.2M | $13.2M | $13.8M | $13.9M | $15.4M | $14.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology